AstraZeneca collaborates with TARIS Biomedical for improved bladder cancer treatments
Privately-held US biotech firm TARIS Biomedical has entered into a research collaboration with Anglo-Swedish drug major AstraZeneca (LSE: AZN) to evaluate novel treatments for bladder cancer.
Under the terms of the agreement, the companies will work together to evaluate multiple novel cancer therapeutics by employing the TARIS proprietary bladder delivery platform in combination with targeted cancer therapeutics from AstraZeneca. The TARIS delivery platform is a soft, flexible system deployed into and retrieved from the bladder using standard urological office procedures. It is designed to provide continuous local delivery to the bladder for days to weeks, depending on the therapeutic application.
Furthermore, AstraZeneca has an exclusive option to take a license to the products resulting from the collaboration. No financial terms of the accord were revealed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze